

Andrés García-Montero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9269144/publications.pdf>

Version: 2024-02-01

107
papers

38,139
citations

81434

41
h-index

39744

98
g-index

107
all docs

107
docs citations

107
times ranked

71182
citing authors

#	ARTICLE	IF	CITATIONS
1	Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis. <i>Blood</i> , 2022, 139, 572-583.	0.6	8
2	Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis. <i>Cancers</i> , 2022, 14, 2487.	1.7	4
3	Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis. <i>American Journal of Human Genetics</i> , 2021, 108, 284-294.	2.6	12
4	Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. <i>Lancet Haematology</i> , 2021, 8, e194-e204.	2.2	39
5	Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 427-434.	0.5	5
6	The Hydrophathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome. <i>Frontiers in Oncology</i> , 2021, 11, 723722.	1.3	0
7	Frequency of clonal mast cell diseases among patients presenting with anaphylaxis: A prospective study in 178 patients from 5 tertiary centers in Spain. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2924-2926.e1.	2.0	7
8	MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2019, 37, 2846-2856.	0.8	82
9	Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 552.	1.8	9
10	Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis. <i>Blood</i> , 2019, 134, 456-468.	0.6	44
11	Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease. <i>Pharmacogenomics Journal</i> , 2019, 19, 547-555.	0.9	4
12	Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 355-364.	0.5	44
13	Impact of somatic and germline mutations on the outcome of systemic mastocytosis. <i>Blood Advances</i> , 2018, 2, 2814-2828.	2.5	42
14	Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 <i>KIT</i> mutations and review of the literature. <i>Oncotarget</i> , 2017, 8, 68950-68963.	0.8	83
15	A genome-wide association study identifies <i>SLC8A3</i> as a susceptibility locus for ACPA-positive rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 1106-1111.	0.9	14
16	KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression. <i>Blood</i> , 2016, 127, 761-768.	0.6	33
17	Urine metabolome profiling of immune-mediated inflammatory diseases. <i>BMC Medicine</i> , 2016, 14, 133.	2.3	97
18	Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients. <i>British Journal of Haematology</i> , 2016, 172, 56-63.	1.2	15

#	ARTICLE	IF	CITATIONS
19	Identification of <i>IRX1</i> as a Risk Locus for Rheumatoid Factor Positivity in Rheumatoid Arthritis in a Genome-Wide Association Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 1384-1391.	2.9	6
20	Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia. <i>Leukemia</i> , 2016, 30, 1753-1756.	3.3	21
21	Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression. <i>Leukemia</i> , 2016, 30, 124-130.	3.3	49
22	Genome-Wide Pathway Analysis Identifies Genetic Pathways Associated with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 593-602.	0.3	27
23	Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 168-178.e1.	1.5	72
24	A deletion at <i>ADAMTS9-MAG11</i> locus is associated with psoriatic arthritis risk. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1875-1881.	0.5	18
25	Identification of Risk Loci for Crohn's Disease Phenotypes Using a Genome-Wide Association Study. <i>Gastroenterology</i> , 2015, 148, 794-805.	0.6	46
26	The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis. <i>Journal of Leukocyte Biology</i> , 2015, 97, 49-59.	1.5	47
27	Detection of the <i>KIT</i> D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. <i>Modern Pathology</i> , 2015, 28, 1138-1149.	2.9	88
28	The impact of sensitive <i>KIT</i> D816V detection on recognition of Indolent Systemic Mastocytosis. <i>Leukemia Research</i> , 2015, 39, 273-278.	0.4	27
29	<i>KIT</i> mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. <i>Leukemia</i> , 2015, 29, 1223-1232.	3.3	229
30	A global reference for human genetic variation. <i>Nature</i> , 2015, 526, 68-74.	13.7	13,998
31	Ex vivo identification and characterization of a population of <i>CD13^{high} CD105⁺ CD45^{low}</i> mesenchymal stem cells in human bone marrow. <i>Stem Cell Research and Therapy</i> , 2015, 6, 169.	2.4	21
32	Phenotypic profile of expanded NK cells in chronic lymphoproliferative disorders: a surrogate marker for NK-cell clonality. <i>Oncotarget</i> , 2015, 6, 42938-42951.	0.8	23
33	<i>KIT</i> D816V Mutation Positive Bone Marrow Mesenchymal Stem Cells in Indolent Systemic Mastocytosis Are Associated with Disease Progression. <i>Blood</i> , 2015, 126, 4058-4058.	0.6	0
34	Implementation of a Cost-Accounting Model in a Biobank: Practical Implications. <i>Pathobiology</i> , 2014, 81, 286-297.	1.9	9
35	P665 A genome-wide association study identifies <i>DSE-FAM26F</i> as a risk locus for ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S348.	0.6	0
36	A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis. <i>Human Molecular Genetics</i> , 2014, 23, 6927-6934.	1.4	39

#	ARTICLE	IF	CITATIONS
37	Integrating sequence and array data to create an improved 1000 Genomes Project haplotype reference panel. <i>Nature Communications</i> , 2014, 5, 3934.	5.8	364
38	Flow Cytometry in Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 297-313.	0.7	14
39	Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 520-528.e5.	1.5	118
40	Human genomic regions with exceptionally high levels of population differentiation identified from 911 whole-genome sequences. <i>Genome Biology</i> , 2014, 15, R88.	13.9	72
41	Cell Purification: A New Challenge for Biobanks. <i>Pathobiology</i> , 2014, 81, 261-275.	1.9	23
42	CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. <i>Histopathology</i> , 2013, 63, 780-787.	1.6	77
43	Integrative Annotation of Variants from 1092 Humans: Application to Cancer Genomics. <i>Science</i> , 2013, 342, 1235-1237.	6.0	341
44	Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1213-1224.e4.	1.5	30
45	Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 605-607.	1.5	27
46	A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300. <i>Gut</i> , 2013, 62, 1440-1445.	6.1	42
47	Flow Cytometry Criteria for Systemic Mastocytosis: Bone Marrow Mast Cell Counts Do Not Always Count. <i>American Journal of Clinical Pathology</i> , 2013, 139, 404-406.	0.4	6
48	Serum Tryptase Monitoring in Indolent Systemic Mastocytosis: Association with Disease Features and Patient Outcome. <i>PLoS ONE</i> , 2013, 8, e76116.	1.1	29
49	Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes. <i>Human Molecular Genetics</i> , 2012, 21, 4549-4557.	1.4	79
50	An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis. <i>Leukemia</i> , 2012, 26, 951-958.	3.3	58
51	Validation of the REMA Score for Predicting Mast Cell Clonality and Systemic Mastocytosis in Patients with Systemic Mast Cell Activation Symptoms. <i>International Archives of Allergy and Immunology</i> , 2012, 157, 275-280.	0.9	126
52	Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion. <i>Modern Pathology</i> , 2012, 25, 516-521.	2.9	55
53	Mast cell-related disorders presenting with Kounis syndrome. <i>International Journal of Cardiology</i> , 2012, 161, 56-58.	0.8	23
54	An integrated map of genetic variation from 1,092 human genomes. <i>Nature</i> , 2012, 491, 56-65.	13.7	7,199

#	ARTICLE	IF	CITATIONS
55	Diagnosis of Adult Mastocytosis: Role for Bone Marrow Analysis. , 2012, , 388-398.		6
56	Current state of biology and diagnosis of clonal mast cell diseases in adults. International Journal of Laboratory Hematology, 2012, 34, 445-460.	0.7	21
57	The variant call format and VCFtools. Bioinformatics, 2011, 27, 2156-2158.	1.8	11,326
58	Evaluation of the WHO criteria for the classification of patients with mastocytosis. Modern Pathology, 2011, 24, 1157-1168.	2.9	89
59	Validation of the REMA Score for Predicting Systemic Mastocytosis in Patients with Mast Cell Activation Disorders. Journal of Allergy and Clinical Immunology, 2011, 127, AB248-AB248.	1.5	0
60	Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis. Haematologica, 2011, 96, e26-e26.	1.7	4
61	Is rigorous retrospective harmonization possible? Application of the DataSHaPER approach across 53 large studies. International Journal of Epidemiology, 2011, 40, 1314-1328.	0.9	84
62	Quality, quantity and harmony: the DataSHaPER approach to integrating data across bioclinical studies. International Journal of Epidemiology, 2010, 39, 1383-1393.	0.9	148
63	Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. Journal of Allergy and Clinical Immunology, 2010, 125, 719-726.e4.	1.5	128
64	Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. Journal of Allergy and Clinical Immunology, 2010, 125, 1269-1278.e2.	1.5	263
65	Clinical, Biological And Molecular Characteristics Of Mast Cell Activation Disorders: A Prospective Study In 62 Patients By The Spanish Network On Mastocytosis (REMA).. Journal of Allergy and Clinical Immunology, 2009, 123, S141-S141.	1.5	8
66	Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. Journal of Allergy and Clinical Immunology, 2009, 124, 514-521.	1.5	252
67	Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. Journal of Allergy and Clinical Immunology, 2008, 121, 519-526.	1.5	117
68	Integral Diagnosis of Adult Mastocytosis. Impact of the Different Clinical, Biologic, Immunophenotypic and Molecular Parameters in the Diagnosis and Classification of the disease. A Prospective Study by Spanish Network on Mastocytosis (REMA) in 191 cases. Journal of Allergy and Clinical Immunology, 2008, 121, S113-S113.	1.5	0
69	Expanded cells in monoclonal TCR- $\alpha^{\pm}\beta^{\pm}$ /CD4+/NK α^+ /CD8 α^{\pm} /+dim T-LGL lymphocytosis recognize hCMV antigens. Blood, 2008, 112, 4609-4616.	0.6	54
70	Monoclonal TCR- $\alpha^{\pm}\beta^{\pm}$ 13.1+/CD4+/NK α^+ /CD8 α^{\pm} /+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin. Blood, 2007, 109, 4890-4898.	0.6	72
71	Association between the HLA haplotype and the TCR- $\alpha^{\pm}\beta^{\pm}$ repertoire of anti-hCMV specific memory T-cells in immunocompetent healthy adults. Cytometry Part B - Clinical Cytometry, 2007, 72B, 371-379.	0.7	7
72	Recent advances in the understanding of mastocytosis: the role of KIT mutations. British Journal of Haematology, 2007, 138, 12-30.	1.2	205

#	ARTICLE	IF	CITATIONS
73	Membrane cholesterol in the regulation of aminophospholipid asymmetry and phagocytosis in oxidized erythrocytes. <i>Free Radical Biology and Medicine</i> , 2007, 42, 1106-1118.	1.3	34
74	Flow Cytometric Analysis of Normal and Neoplastic Mast Cells: Role in Diagnosis and Follow-Up of Mast Cell Disease. <i>Immunology and Allergy Clinics of North America</i> , 2006, 26, 535-547.	0.7	47
75	Management of Type II Systemic Mastocytosis (SM-AHNMD) with Hydroxyurea. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, S70.	1.5	1
76	Indolent Systemic Mastocytosis with Germline D816V Somatic c-kit Mutation Evolving to an Acute Myeloid Leukemia. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, S125.	1.5	2
77	KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. <i>Blood</i> , 2006, 108, 2366-2372.	0.6	447
78	Redox-sensitive modulation of CD45 expression in pancreatic acinar cells during acute pancreatitis. <i>Journal of Pathology</i> , 2006, 210, 234-239.	2.1	18
79	Combined vaccination with idiotypic-pulsed allogeneic dendritic cells and soluble protein idiotypic for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2006, 47, 29-37.	0.6	60
80	CD45 expression on rat acinar cells: Involvement in pro-inflammatory cytokine production. <i>FEBS Letters</i> , 2005, 579, 6355-6360.	1.3	23
81	A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation. <i>Laboratory Investigation</i> , 2004, 84, 1387-1398.	1.7	52
82	Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). , 2004, 58B, 1-8.		130
83	Systemic mastocytosis associated with acute myeloid leukemia: case report and implications for disease pathogenesis. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 28-33.	1.5	20
84	Clinicobiological, Immunophenotypic, and Molecular Characteristics of Monoclonal CD56 ⁺ /dim Chronic Natural Killer Cell Large Granular Lymphocytosis. <i>American Journal of Pathology</i> , 2004, 165, 1117-1127.	1.9	60
85	Molecular Characterization of a Novel Immune Receptor Restricted to the Monocytic Lineage. <i>Journal of Immunology</i> , 2004, 173, 6703-6711.	0.4	51
86	Mice with targeted disruption of p8 gene show increased sensitivity to lipopolysaccharide and DNA microarray analysis of livers reveals an aberrant gene expression response. <i>BMC Gastroenterology</i> , 2003, 3, 25.	0.8	42
87	The pancreatitis-associated protein induces lung inflammation in the rat through activation of TNF α expression in hepatocytes. <i>Journal of Pathology</i> , 2003, 199, 398-408.	2.1	29
88	Flow Cytometric Analysis of Cytokine Responses in Stimulated Whole Blood: Simultaneous Quantitation of TNF- α - β -Secreting Cells and Soluble Cytokines. , 2003, Chapter 9, Unit 9.21.		0
89	A new method for detecting TNF- α -secreting cells using direct-immunofluorescence surface membrane stainings. <i>Journal of Immunological Methods</i> , 2002, 264, 77-87.	0.6	30
90	p8-deficient fibroblasts grow more rapidly and are more resistant to adriamycin-induced apoptosis. <i>Oncogene</i> , 2002, 21, 1685-1694.	2.6	80

#	ARTICLE	IF	CITATIONS
91	Transforming growth factor β -1 enhances Smad transcriptional activity through activation of p8 gene expression. <i>Biochemical Journal</i> , 2001, 357, 249.	1.7	34
92	Transforming growth factor β -1 enhances Smad transcriptional activity through activation of p8 gene expression. <i>Biochemical Journal</i> , 2001, 357, 249-253.	1.7	46
93	Expression of the stress-induced p8 mRNA is transiently activated after culture medium change. <i>European Journal of Cell Biology</i> , 2001, 80, 720-725.	1.6	51
94	Selective exocytosis of zymogen granules induces non-parallel secretion in short-term cholecystokinin-stimulated rats. <i>Journal of Endocrinology</i> , 1999, 163, 199-206.	1.2	7
95	Zymogen granule alterations in caerulein-induced pancreatitis developed during continuous hydrocortisone administration. <i>European Journal of Clinical Investigation</i> , 1999, 29, 496-503.	1.7	5
96	The recovery of acute pancreatitis depends on the enzyme amount stored in zymogen granules at early stages. <i>Molecular and Cellular Biochemistry</i> , 1999, 200, 35-41.	1.4	5
97	Structural and functional characterization of the mouse p8 gene: promotion of transcription by the CAAT-enhancer binding protein β (C/EBP β) and C/EBP β trans-acting factors involves a C/EBP cis-acting element and other regions of the promoter. <i>Biochemical Journal</i> , 1999, 343, 377-383.	1.7	39
98	Structural and functional characterization of the mouse p8 gene: promotion of transcription by the CAAT-enhancer binding protein β (C/EBP β) and C/EBP β trans-acting factors involves a C/EBP cis-acting element and other regions of the promoter. <i>Biochemical Journal</i> , 1999, 343, 377.	1.7	18
99	Effect of cholecystokinin blockade on the recovery of alterations induced by acute pancreatitis in glycoconjugates of rat zymogen granules. <i>Glycoconjugate Journal</i> , 1998, 15, 923-928.	1.4	3
100	Long-Term Blockade of Cholecystokinin (CCK). <i>Pancreas</i> , 1997, 15, 314-322.	0.5	4
101	Hydrocortisone induces an increase of amylase content in individual zymogen granules from rat pancreas. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1997, 62, 439-448.	1.2	6
102	Cholecystokinin regulates glycoprotein membrane composition of rat pancreatic zymogen granules. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1997, 1326, 131-137.	1.4	7
103	Glucocorticoids regulate l-fucose glycoconjugates in rat pancreatic zymogen granules. <i>Molecular and Cellular Endocrinology</i> , 1997, 133, 117-125.	1.6	5
104	Enzyme Changes in Zymogen Granules and in Pancreatic Secretion Throughout Long-Term CCK Treatment. <i>Peptides</i> , 1997, 18, 101-110.	1.2	22
105	Effects of the Cholecystokinin Receptor Antagonist L-364,718 on Pancreatitis Induced by a Deficient in Choline and Supplemented with Ethionine (CDE) Diet in the Rat. <i>Archives of Physiology and Biochemistry</i> , 1995, 103, 410-415.	1.0	0
106	Adrenalectomy induces a decrease in the light scatter properties and amylase content of isolated zymogen granules from rat pancreas as analyzed by flow cytometry. <i>Journal of Endocrinology</i> , 1995, 147, 431-440.	1.2	8
107	Therapeutic and Protective Effect of Subcutaneous Injections of L-364, 718 on Caerulein-Induced Acute Pancreatitis. <i>Pancreas</i> , 1994, 9, 309-315.	0.5	24